Tesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue

Is tesofensine a peptide?

Tesofensine sits in peptide shops next to semaglutide and BPC-157, and people who haven't checked call it a 'peptide for weight loss'. It is a brain-acting drug in the same broad family as sibutramine and bupropion. It raises three brain chemicals between nerve cells, which cuts appetite. Nothing about it is a chain of protein building blocks. It is still being tested: a big study done in one country, approved in none.

Where did tesofensine come from?

The 2008 Obesity review is the cleanest look at tesofensine in people who weren't trying to lose weight. Across the four brain-disease studies, weight at 14 weeks went up 0.5 percent on the dummy pill. It went down 0.5, 0.9, 1.8 and 2.8 percent on 0.125, 0.25, 0.5 and 1.0 mg. 'No effect on blood pressure was observed', but heart rate clearly rose from the 0.25 mg dose up (PubMed 18356831). Weight was a side measure here, not the main goal. The authors concluded that tesofensine was 'now being developed for obesity management'.

What happened in the big study in Mexico?

The Viking results exist only as a press release. Both doses beat the dummy pill. Waist size, belly fat and blood fats (triglycerides) improved. The release notes a 'low but statistically significant increase in heart rate', with no real change in blood pressure (Saniona press release, December 17, 2018). As far as we can find, it was never published in a journal. The path since has been slow. An expert panel gave a favorable but non-binding view in February 2023. On November 6, 2024, the company said COFEPRIS had not approved the application, and pointed to safety data on about 1,600 patients (Saniona, November 6, 2024). On February 20, 2025, it sent the whole application again, roughly 20,000 pages (Saniona, February 20, 2025). We searched for a later decision and found none as of September 8, 2026. Claims that tesofensine is 'approved in Mexico' are wrong, going by the public record.

What did the 2008 Lancet study show?

This is where the 'about 10 percent' figure comes from, and the weight numbers are real (PubMed 18950853). The authors wrote that 0.5 mg 'might have the potential to produce a weight loss twice that of currently approved drugs'. That was before the GLP-1 drugs (see our GLP-1 field guide). Two catches. First, blood pressure did not clearly rise at 0.25 and 0.5 mg, but the summary says nothing about the 1.0 mg group, and later studies used only 0.25 and 0.5 mg. Second, in 2011 the Danish medicines regulator inspected the study and found problems at two of the five sites. Staff who weren't medical had taken consent, and side effects were not fully recorded. The Lancet published a formal Expression of Concern in April 2013. The inspection confirmed the main results and serious side effects against the original records. But it found the published side-effect picture 'is not in accordance with the actual course of the trial' (Retraction Watch, 2013).

Why is heart rate the problem?

The heart-rate rise shows up in every tesofensine study, and drugs like it have a poor history. Sibutramine, which also keeps noradrenaline and serotonin around, was pulled in 2010. The SCOUT study, in people already at risk of heart disease, found 16 percent more heart attacks, strokes and heart deaths on it (New England Journal of Medicine, 2010). The Tesomet program is the company's own admission of the problem. In the European Journal of Endocrinology study, 21 adults with hypothalamic obesity took Tesomet or a dummy pill for 24 weeks, and 18 finished. Side effects included trouble sleeping (50 against 13 percent), dry mouth (43 against 0) and headache (36 against 0). 'No significant differences in heart rate or blood pressure were observed between groups' (PubMed 35294397). A gray-market capsule gives you the tesofensine without the heart drug, without a doctor watching, and without the 1,600-patient safety record that a regulator still isn't happy with.

How does tesofensine compare with phentermine?

The numbers make tesofensine look stronger than phentermine. The evidence says that isn't proven. The Aronne study gave adults with obesity a dummy pill, phentermine alone, topiramate alone or both together for 28 weeks, with lifestyle coaching. The pair took off 8.5 to 9.2 percent, against 1.7 percent on the dummy pill, and each drug alone did clearly less (PubMed 24136928). Phentermine has decades of prescribing and a label with heart warnings. Tesofensine has one published mid-sized study with a journal warning attached, a big study known only from a press release and no approval. GLP-1 peptides took off much more weight over longer studies; see the semaglutide profile.

Why do peptide vendors sell it?

There is also a practical reason it travels with peptides. Unlike phentermine, it isn't a controlled drug. It is cheap to make. And it takes roughly eight days for half of it to leave the body, so one pill a day builds up slowly, which buyers read as 'gentle'. A capsule from an unregulated seller has no checked identity, purity or dose. Our guide to reading a peptide lab certificate explains why a seller's certificate doesn't settle that. The FDA status tracker explains why 'research use only' is not a legal category for a drug a person takes. Tesofensine was not part of the July 2026 pharmacy votes, and there is no legal way to get it in the US.

The bottom line

Tesofensine is a real drug. It took off real weight in a mid-sized study. It also raises heart rate every time, so much that its own maker built a combination product to cancel that out. Its big study has never been published, its Lancet paper carries a journal warning, and Mexico's regulator has had some form of its application since before 2023 without approving it. It is not a peptide and it is not approved. That it shows up in peptide catalogs says more about how those catalogs are put together than about the drug.